MRTX News and Press, Mirati Therapeutics Inc. From 09/18/20

SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO ® ) in patients with ...

Germany-based Boehringer Ingelheim will collaborate with Mirati Therapeutics  (NASDAQ: MRTX ) on a clinical trial evaluating the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and the latter's MRTX849, a...

INGELHEIM, Germany and SAN DIEGO , Sept. 17, 2020 /PRNewswire/ -- Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation t...

SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will participate in a fireside chat at the Citi 15 th Annual Biopharma Virtual Conference on Thursday, September 10, 2020 at 11:40...

ANN ARBOR, Mich. , Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with Mirati Therapeutics, Inc. (NASDAQ:MRTX) to broaden patient identification and enrollme...

Mirati Therapeutics (NASDAQ: MRTX ) : Q2 GAAP EPS of -$1.89 beats by $0.20 . More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020 . "Mirati is working to design, develop and deliver novel on...

ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor IND filing to support clinical development of ORIC-944 in prostate cancer expected in 2H 2021 ORIC to host conference call today at 4:30 p.m. ET SOUTH SAN FRANC...

Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-ca p biotechnology stocks. These companies are often selling at attractive prices, and the...

SAN DIEGO , June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41 st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 . Charles M. Baum , M.D., Ph.D.,...